Ye Liu

机构：Shanghai Changzheng Hospital · ORCID：0000-0003-1716-7037

发表论文 47 篇 · 总被引 1654 次 · h-index 19

代表论文

Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study (2022 · The Lancet Haematology · 被引 95)
Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage (2021 · FEBS Open Bio · 被引 80)
Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy (2024 · Blood · 被引 75)
Research progress on the immune microenvironment and immunotherapy in gastric cancer (2023 · Frontiers in Immunology · 被引 51)
Emerging Trends and Research Foci in Tumor Microenvironment of Pancreatic Cancer: A Bibliometric and Visualized Study (2022 · Frontiers in Oncology · 被引 37)
A Synergistic Chemoimmunotherapy System Leveraging PD‐L1 Blocking and Bioorthogonal Prodrug Activation (2024 · Advanced Materials · 被引 32)